Drugs for Congenital Cytomegalovirus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 21)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Anti-Infective Agents |
|
Phase 4,Phase 3,Phase 2,Phase 1 |
|
|
|
2 |
|
Antiviral Agents |
|
Phase 4,Phase 3,Phase 2,Phase 1 |
|
|
|
3 |
|
Acyclovir |
|
Phase 4,Phase 2,Phase 3 |
|
|
|
4 |
|
valacyclovir |
|
Phase 4,Phase 2,Phase 3 |
|
|
|
5 |
|
Ganciclovir |
Approved, Investigational |
Phase 3,Phase 2,Phase 1 |
|
82410-32-0 |
3454
|
Synonyms:
106931-35-5
107910-75-8 (mono-hydrochloride salt)
2-(6-Amino-purin-9-ylmethoxy)-propane-1,3-diol
2-Amino-1,9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-6-H-purin-6-one
2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-1H-purin-6(9H)-one
2-amino-9-((1,3-Dihydroxypropan-2-yloxy)methyl)-1H-purin-6(9H)-one
2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one
2-amino-9-((1,3-Dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one
2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-9H-purin-6-ol
2-amino-9-((1,3-Dihydroxypropan-2-yloxy)methyl)-9H-purin-6-ol
2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)-3H-purin-6-one
2-Amino-9-(2-hydroxy-1-hydroxymethyl-ethoxymethyl)-1,9-dihydro-purin-6-one
2-amino-9-(2-hydroxy-1-hydroxymethylethoxymethyl)-6,9-dihydro-1H-6-purinone
2-amino-9-(2-Hydroxy-1-hydroxymethylethoxymethyl)-6,9-dihydro-1H-6-purinone
2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-1,9-dihydro-6H-purin-6-one
2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-6,9-dihydro-3H-purin-6-one
2'-NDG
2'-Nor-2'-deoxyguanosine
82410-32-0
86357-12-2
9-((1,3-Dihydroxy-2-propoxy)methyl)guanine
9-((2-Hydroxy-1-(hydroxymethyl)ethoxy)methyl)guanine
9-(1,3-DIHYDROXY-PROPOXYMETHANE)GUANINE
9-[(1,3-dihydroxy-2-propoxy)methyl]guanine
9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine
96551-29-0
AC-12604
AC1L1FZ2
AC1Q52OB
AKOS004119898
BB_NC-1042
BIDD:GT0783
Biolf 62
BIOLF-62
BPBio1_000877
BSPBio_000797
BW 759
BW 759U
BW-759U
BW-795
BW-B 759U
CAS-82410-32-0
CCRIS 9212
CHEBI:465284
CHEMBL182
CID3454
Citovirax
CPD000058324
Cymevan
Cymeven
Cymevene
Cytovene
Cytovene (TN)
Cytovene-IV
D00333
DB01004
DRG-0018
EU-0100539
G 2536
|
G2536_SIGMA
GA2
ganciclovir
Ganciclovir
Ganciclovir & C34-dgA immunotoxin
Ganciclovir & D5-dgA immunotoxin
Ganciclovir (JAN/USP/INN)
Ganciclovir [USAN:INN:BAN:JAN]
GANCICLOVIR SODIUM
Ganciclovirum
Ganciclovirum [Latin]
Gancyclovir
GCV & 1110U81
GCV & MSL
Guanine, 9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)- and MSL, neutralizing monoclonal antibody
HHEMG
HMS1570H19
HMS2090K08
HSDB 6512
Hydroxyacyclovir
I07-0010
IN1478
Lopac0_000539
Lopac-G-2536
LS-73939
MB3795
MLS000028481
MLS001077349
MolPort-000-758-398
MolPort-002-507-301
NCGC00015471-01
NCGC00015471-02
NCGC00015471-03
NCGC00015471-06
NCGC00093928-01
NCGC00093928-02
NCGC00168567-01
nchembio.87-comp3
PDSP1_000816
PDSP2_000803
Prestwick_1068
Prestwick0_000839
Prestwick1_000839
Prestwick2_000839
Prestwick3_000839
RS-21592
SAM002548936
SMP2_000038
SMR000058324
SPBio_002718
ST-605
STK801910
UNII-P9G3CKZ4P5
Virgan
Vitrasert
Vitrasert (TN)
ZINC00001505
Zirgan
|
|
6 |
|
Valganciclovir |
Approved, Investigational |
Phase 3,Phase 2,Phase 1 |
|
175865-60-8 |
64147
|
Synonyms:
[2-[(2-amino-6-oxo-3H-purin-9-yl)methoxy]-3-hydroxypropyl] (2S)-2-amino-3-methylbutanoate
175865-60-8
5-Amino-3-[1-(hydroxymethyl)-2-(L-valyloxy)ethoxymethyl]-6,7-dihydro-3H-imidazo[4,5-d]pyrimidin-7-one
AC1L20JF
AC1Q63EV
C14H22N6O5
CID64147
Cymeval
D02495
DB01610
I06-1704
LS-173677
L-Valine, 2-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)-3-hydroxypropyl ester
|
L-valine, ester with ganciclovir
L-Valine, ester with ganciclovir
NCGC00168779-01
RO1079070/194
RS 79070
UNII-GCU97FKN3R
Valcyt
Valcyte
valganciclovir
Valganciclovir
Valganciclovir (INN)
Valganciclovir (Oral)
Valganciclovir [INN:BAN]
|
|
7 |
|
Mannitol |
Approved, Investigational |
Phase 3 |
|
69-65-8 |
6251
453
|
Synonyms:
(2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexaol
(2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol
(2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexol
(L)-Mannitol
1,2,3,4,5,6-Hexanehexol
123897-58-5
133-43-7
15719_ALDRICH
15719_RIEDEL
33440_RIEDEL
33440_SIGMA
36413-61-3
4-01-00-02841 (Beilstein Handbook Reference)
5149-40-6
63559_FLUKA
63559_SIGMA
63560_FLUKA
63565_FLUKA
63565_SIGMA
69-65-8
75398-80-0
85085-15-0
87-78-5
AB1002081
AC-12776
AC1L1M49
AC1Q28E5
AI3-19511
Ambap69-65-8
AR-1J3861
bmse000099
BRN 1721898
C00392
C6H14O6
CCRIS 369
CHEBI:16899
CHEMBL689
CID6251
Cordycepate
Cordycepic acid
cpd without stereochemical designation
D-(-)-Mannitol
D00062
D008353
Diosmol
DL-Mannitol
D-mannite
D-mannitol
D-Mannitol
D-Mannitol (JP15)
e 421
e421
ED1D1E61-FEFB-430A-AFDC-D1F4A957FC3D
EINECS 200-711-8
EINECS 201-770-2
Fraxinine
Hexahydroxyhexane
Hexanhexol
HSDB 714
Invenex
Isotol
LS-1588
LS-89250
M0044
M1902_SIGMA
M4125_SIAL
M8429_SIAL
M9546_SIAL
|
M9647_SIAL
Manicol
manita
Manitol
Maniton S
Maniton-S
Manna sugar
Manna Sugar
Mannazucker
Mannidex
Mannidex 16700
Mannigen
Mannistol
Mannit
Mannit p
Mannite
mannitol
Mannitol
Mannitol (USP)
Mannitol (VAN)
Mannitol [USAN]
Mannitol 10%
Mannitol 10% In Plastic Container
MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER
Mannitol 15%
Mannitol 15% In Plastic Container
MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%
Mannitol 20%
Mannitol 20% In Plastic Container
MANNITOL 25%
Mannitol 5%
Mannitol 5% In Plastic Container
MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%
Mannitolum
Mannogem 2080
Marine crystal
Marine Crystal
MLS001335977
MLS001335978
MolPort-003-927-039
MTL
Mushroom sugar
NCGC00164246-01
NCI-C50362
NSC 407017
NSC 9256
Osmitrol
Osmitrol (TN)
Osmitrol 10% In Water
OSMITROL 10% IN WATER IN PLASTIC CONTAINER
Osmitrol 15% In Water
OSMITROL 15% IN WATER IN PLASTIC CONTAINER
Osmitrol 20% In Water
OSMITROL 20% IN WATER IN PLASTIC CONTAINER
Osmitrol 5% In Water
OSMITROL 5% IN WATER IN PLASTIC CONTAINER
Osmofundin
Osmosal
Resectisol
Resectisol In Plastic Container
SDM No. 35
SMR000857324
Sorbitol-Mannitol
SORBITOL-MANNITOL IN PLASTIC CONTAINER
TL806434
UNII-3OWL53L36A
ZINC02041302
|
|
8 |
|
Povidone |
Approved |
Phase 3 |
|
9003-39-8 |
|
Synonyms:
1-Ethenyl-2-pyrrolidinone
1-Ethenyl-2-Pyrrolidinone
1-Ethenyl-2-pyrrolidinone (9CI)
1-Ethenyl-2-pyrrolidinone homopolymer
1-Ethenyl-2-pyrrolidinone homopolymer, 9CI
1-Ethenyl-2-pyrrolidinone polymers
1-Ethenyl-2-pyrrolidinone, homopolymer
1-Vinyl-2-pyrrolidinone
1-Vinyl-2-Pyrrolidinone
1-Vinyl-2-pyrrolidinone cross-linked insoluble polymer
1-Vinyl-2-pyrrolidinone homopolymer
1-Vinyl-2-pyrrolidinone polymer
1-Vinyl-2-pyrrolidinone, monomer
1-Vinyl-2-pyrrolidinone, polymer
1-Vinyl-2-pyrrolidone
1-Vinyl-2-pyrrolidone polymer
1-Vinylpyrrolidin-2-one
1-Vinylpyrrolidinone
1-Vinylpyrrolidone
2-Pyrrolidinone, 1-ethenyl, homopolymer
2-Pyrrolidinone, 1-ethenyl-, homopolymer
2-Pyrrolidinone, 1-vinyl-, polymers
Agent AT 717
Agent AT-717
Agrimer
Albigen a
Aldacol q
Antaron P 804
Bolinan
Crospovidone
Disadine
Ganex P 804
Ganex P-804
Hemodesis
Hemodez
K 115 (Polyamide)
K 25 (Polymer)
K 25 (VAN)
K 30 (Polymer)
K 30 (VAN)
K 60 (Polymer)
K 60 (VAN)
K115 (polyamide)
K25 (polymer)
K30 (polymer)
K60 (polymer)
Kollidin CLM
Kollidon
Kollidon 17
Kollidon 25
'Kollidon 25'
Kollidon 30
Kollidon CL
Luviskol
Luviskol K 30
Luviskol K 90
Luviskol K30
Luviskol K-30
Luviskol K90
Neocompensan
N-Vinyl pyrrolidone
N-Vinyl-2-pyrrolidinone
N-Vinyl-2-pyrrolidone
N-Vinyl-2-pyrrolidone polymer
N-Vinylbutyrolactam polymer
N-Vinylpyrrolidinone
N-Vinylpyrrolidinone polymer
N-Vinylpyrrolidone
N-Vinylpyrrolidone polymer
N-Vinylpyrrolidone-2
Peragal ST
Peregal ST
Periston
Periston-N
Peviston
'plasdone'
Plasdone
Plasdone 4
Plasdone K 29-32
Plasdone K-26/28
Plasdone No. 4
|
Plasdone XL
Plasmosan
Polividone [dcit]
Poly(1-(2-oxo-1-pyrrolidinyl)-1,2-ethanediyl)
Poly(1-(2-oxo-1-pyrrolidinyl)ethylene)
Poly(1-ethenyl-2-pyrrolidinone)
Poly(1-vinyl-2-pyrrolidinone)
Poly(1-vinyl-2-pyrrolidinone) homopolymer
Poly(1-vinyl-2-pyrrolidinone) hueper'S polymer no.1
Poly(1-vinyl-2-pyrrolidinone) hueper'S polymer no.2
Poly(1-vinyl-2-pyrrolidinone) hueper'S polymer no.3
Poly(1-vinyl-2-pyrrolidinone) hueper'S polymer no.4
Poly(1-vinyl-2-pyrrolidinone) hueper'S polymer no.5
Poly(1-vinyl-2-pyrrolidinone) hueper'S polymer no.6
Poly(1-vinyl-2-pyrrolidinone) hueper'S polymer no.7
Poly(1-vinyl-2-pyrrolidone)
Poly(1-vinylpyrrolidinone)
Poly(N-vinyl-2-pyrrolidinone)
Poly(N-vinyl-2-pyrrolidone)
Poly(N-vinylbutyrolactam)
Poly(N-vinylpyrrolidinone)
Poly(N-vinylpyrrolidone)
Poly(vinylpolypyrrolidone)
Poly(vinylpyrrolidinone)
Poly(vinylpyrrolidone)
Polyclar a. t
Polyclar a. t.
Polyclar at
Polyclar h
Polyclar L
Polyclar-at
Polygyl
Poly-N-vinyl pyrrolidone
Poly-N-vinylpyrrolidone
Polyplasdone
Polyplasdone XL
Polyvidonum
Polyvinyl pyrrolidone
Polyvinylpolypyrrolidone
Polyvinylpyrrolidone
Polyvinylpyrrolidone polymers
Polyvinylpyrrolidone, cross-linked
Povidone
Povidone (usp xix)
Povidone [usan:inn:ban]
Povidone(usan)
Povidone, BAN, USAN
Protagent
PVP 1
PVP 2
PVP 3
PVP 4
PVP 5
PVP 6
PVP 7
PVP K 3
PVP10_SIAL
PVP40_SIAL
PVP-K 15
PVP-K 3
PVP-K 30
PVP-K 60
PVP-K 90
PVPP
Refresh
Sauflon
Soothe
Subtosan
Tears plus
Tolpovidone I 131 [USAN:INN]
Tolpovidone I-131
Toxobin
Vinisil
Vinyl-2-pyrrolidone
Vinylbutyrolactam
Vinylpyrrolidinone
Vinylpyrrolidinone polymer
Vinylpyrrolidone
Vinylpyrrolidone polymer
V-Pyrol
|
|
9 |
|
Rho(D) Immune Globulin |
|
Phase 3 |
|
|
|
10 |
|
gamma-Globulins |
|
Phase 3 |
|
|
|
11 |
|
Ganciclovir triphosphate |
|
Phase 3,Phase 2,Phase 1 |
|
|
|
12 |
|
Pharmaceutical Solutions |
|
Phase 3,Phase 2 |
|
|
|
13 |
|
Immunoglobulins |
|
Phase 3,Phase 1,Phase 2 |
|
|
|
14 |
|
Immunoglobulins, Intravenous |
|
Phase 3 |
|
|
|
15 |
|
Antibodies |
|
Phase 3,Phase 1,Phase 2 |
|
|
|
16 |
|
Sodium Benzoate |
|
Phase 3 |
|
|
|
17 |
|
Nucleic Acid Synthesis Inhibitors |
|
Phase 3,Phase 1,Phase 2 |
|
|
|
18 |
|
MF59 oil emulsion |
|
Phase 2 |
|
|
|
19 |
|
Vaccines |
|
Phase 2,Phase 1 |
|
|
|
20 |
|
Antibodies, Monoclonal |
|
Phase 1, Phase 2 |
|
|
|
21 |
|
Krestin |
|
|
|
|
|
Interventional clinical trials:
(show all 36)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
In UTERO Treatment of Cytomegalovirus Congenital Infection With Valacyclovir |
Terminated |
NCT01037712
|
Phase 4 |
Valacyclovir (ZELITREX);Placebo |
2 |
Congenital Cytomegalovirus: Efficacy of Antiviral Treatment |
Unknown status |
NCT02005822
|
Phase 3 |
Valganciclovir |
3 |
A Phase III Study to Evaluate the Safety and Efficacy of Ganciclovir (Dihydroxypropoxymethyl Guanine [DHPG]) Treatment of Symptomatic Central Nervous System (CNS) Congenital Cytomegalovirus (CMV) Infections. |
Completed |
NCT00001100
|
Phase 3 |
ganciclovir |
4 |
Phase III Randomized, Controlled Study of Ganciclovir for Symptomatic Congenital Cytomegalovirus Infection |
Completed |
NCT00004278
|
Phase 3 |
ganciclovir |
5 |
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections |
Completed |
NCT00466817
|
Phase 3 |
Valganciclovir |
6 |
A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV) |
Recruiting |
NCT01376778
|
Phase 3 |
CMV hyperimmune globulin |
7 |
Valacyclovir to Prevent Vertical Transmission of Cytomegalovirus After Maternal Primary Infection During Pregnancy |
Recruiting |
NCT02351102
|
Phase 2, Phase 3 |
Valacyclovir;Placebo |
8 |
Evaluation of the Benefit of Antiviral Treatment With Valganciclovir on Congenital CMV Infection-related Deafness on Hearing and Balance |
Not yet recruiting |
NCT02606266
|
Phase 2, Phase 3 |
Valganciclovir |
9 |
Myocardial Screening in Fetuses With Congenital Cytomegalovirus (CMV) Infection |
Not yet recruiting |
NCT02787382
|
Phase 3 |
|
10 |
Randomized Controlled Trial of Valganciclovir for Asymptomatic Cytomegalovirus Infected Hearing Impaired Infants |
Not yet recruiting |
NCT03107871
|
Phase 3 |
Valganciclovir;Simple Syrup |
11 |
Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Randomized Controlled Trial |
Terminated |
NCT01655212
|
Phase 3 |
Valganciclovir |
12 |
Valganciclovir in Congenital CMV Infants |
Completed |
NCT00031434
|
Phase 1, Phase 2 |
Valganciclovir;Ganciclovir |
13 |
Phase I/II Study of Human Anti-Cytomegalovirus (CMV) Monoclonal Antibody MSL-109 in Newborns With Symptomatic Congenital CMV Infection Without Central Nervous System Disease |
Completed |
NCT00004642
|
Phase 1, Phase 2 |
SDZ MSL-109 |
14 |
Recombinant CMV gB Vaccine in Postpartum Women |
Completed |
NCT00125502
|
Phase 2 |
MF59 adjuvant;Placebo |
15 |
Congenital CMV and Hearing Loss in Children up to 4 Years of Age: Treating With Valganciclovir Therapy |
Recruiting |
NCT01649869
|
Phase 2 |
Valcyte (Valganciclovir hydrochloride) Powder for oral solution;Placebo |
16 |
Asymptomatic Congenital CMV Treatment |
Not yet recruiting |
NCT03301415
|
Phase 2 |
Valganciclovir |
17 |
Safety, Tolerability, and Immunogenicity of a Cytomegalovirus DNA Vaccine |
Withdrawn |
NCT02594566
|
Phase 1 |
CyMVectin |
18 |
A Cross-sectional Study of Congenital Cytomegalovirus Infection in Newborns in China |
Unknown status |
NCT02710864
|
|
|
19 |
Evaluation of the Safety and Efficacy of Standard Intravenous Immunoglobulins in Pregnant Women With Primary Cytomegalovirus Infection |
Unknown status |
NCT01659684
|
|
|
20 |
Genotyping of Cytomegalovirus From Patients in Israel |
Unknown status |
NCT00228202
|
|
|
21 |
The Benefits Feasibility and Acceptability of Extended Screening Testing in Newborn Babies Who Are Referred for Further Hearing Assessment |
Completed |
NCT01162330
|
|
|
22 |
Clinical Trial of Behavioral Modification to Prevent Congenital Cytomegalovirus |
Completed |
NCT01819519
|
|
|
23 |
Neonatal CMV-Ganciclovir Follow-up Study |
Completed |
NCT00031421
|
|
|
24 |
Study of the Transmission of Cytomegalovirus (CMV) Infection From Mother to Foetus |
Completed |
NCT01251744
|
|
|
25 |
Does Normal Brain Imaging Predict Normal Neurodevelopmental Outcome in Fetuses With Proven Cytomegalovirus Infection? |
Completed |
NCT00872703
|
|
|
26 |
Assesment of Olfactory Disorders and Performance of a New Olfactory Test in Children With Congenital CMV |
Recruiting |
NCT02782988
|
|
|
27 |
Diagnosis of Congenital CMV Infection in Neonates Who Failed Newborn Hearing Screening |
Recruiting |
NCT02139423
|
|
|
28 |
A Cohort Study of Cytomegalovirus(CMV) Infection Among Pregnant Women and Their Newborns in China |
Recruiting |
NCT02645396
|
|
|
29 |
Cytomegalovirus Testing and Intervention Protocol for Newborn Nursery and Newborn Intensive Care Unit |
Recruiting |
NCT02680743
|
|
|
30 |
Prognostic Value of Neonatal Markers (Clinical, Imaging and Biological) for the Development of Neurosensorial Sequelae in Children Infected by Cytomegalovirus (CMV) in Utero |
Recruiting |
NCT01923636
|
|
|
31 |
Biomarkers of Cytomegalovirus Fetal Infection and Disease |
Recruiting |
NCT03090841
|
|
|
32 |
Immunological Characteristics of Maternal-fetal Transmission of Cytomegalovirus in Pregnancy |
Recruiting |
NCT02129465
|
|
|
33 |
Relevance of Gastric Aspirate in HCMV Detection |
Recruiting |
NCT03262194
|
|
|
34 |
Screening for Congenital Cytomegalovirus Infection in Newborns |
Enrolling by invitation |
NCT02683096
|
|
|
35 |
Development of Potential Biomarkers for Foetal Brain Development After Congenital CMV Infection |
Not yet recruiting |
NCT03188679
|
|
|
36 |
Cytomegalovirus (CMV) Vaccines: Reinfection and Antigenic Variation |
Not yet recruiting |
NCT03443791
|
|
|
|